RNF125 antibody - middle region
Rabbit Polyclonal Antibody
- 产品详情
- 实验流程
Application ![]()
| WB |
---|---|
Primary Accession | Q96EQ8 |
Other Accession | NM_017831, NP_060301 |
Reactivity | Human, Mouse, Rat, Rabbit, Pig, Dog, Guinea Pig, Horse, Bovine |
Predicted | Mouse, Rat, Rabbit, Dog, Guinea Pig, Bovine |
Host | Rabbit |
Clonality | Polyclonal |
Calculated MW | 26454 Da |
Gene ID | 54941 |
---|---|
Alias Symbol | FLJ20456, MGC21737, TRAC1, TRAC-1 |
Other Names | E3 ubiquitin-protein ligase RNF125, 6.3.2.-, RING finger protein 125, T-cell RING activation protein 1, TRAC-1, RNF125 |
Format | Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. |
Reconstitution & Storage | Add 50 ul of distilled water. Final anti-RNF125 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles. |
Precautions | RNF125 antibody - middle region is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | RNF125 (HGNC:21150) |
---|---|
Function | E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of target proteins, such as RIGI, MAVS/IPS1, IFIH1/MDA5, JAK1 and p53/TP53 (PubMed:15843525, PubMed:17460044, PubMed:17643463, PubMed:25591766, PubMed:26027934, PubMed:26471729, PubMed:27411375). Acts as a negative regulator of type I interferon production by mediating ubiquitination of RIGI at 'Lys- 181', leading to RIGI degradation (PubMed:17460044, PubMed:26471729). Mediates ubiquitination and subsequent degradation of p53/TP53 (PubMed:25591766). Mediates ubiquitination and subsequent degradation of JAK1 (PubMed:26027934). Acts as a positive regulator of T-cell activation (PubMed:15843525). |
Cellular Location | Golgi apparatus membrane; Lipid-anchor. Note=Shows a reticular staining pattern within the cell and is probably expressed at other intracellular membranes in addition to the Golgi membrane. Not detected at the plasma membrane. |
Tissue Location | Predominantly expressed in lymphoid tissues, including bone marrow, spleen and thymus. Also weakly expressed in other tissues. Predominant in the CD4(+) and CD8(+) T-cells, suggesting that it is preferentially confined to T-cells |
Research Areas
For Research Use Only. Not For Use In Diagnostic Procedures.
Application Protocols
Provided below are standard protocols that you may find useful for product applications.

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.